Prostate Cancer

Immunotherapy and Gene Therapy Used against Prostate Cancer

Published in Gene Therapy Weekly, March 30th, 1998

Enzyme-directed prodrug therapies (EPT) and an immunotherapy approach were presented at a recent conference as weapons in the war against prostate cancer.

R. Martiniello, representing colleagues from several centers in Australia, noted that advanced prostate cancer is invariably lethal once it becomes hormone refractory. At the 89th Annual Meeting of the American Association for Cancer Research, held March 28 - April 1, 1998, in New Orleans, Louisiana, Martiniello et al. presented results from their efforts to incorporate EPT in the arsenal against androgen-independent prostate cancer (abstract "Gene Therapy for Prostate Cancer: Comparison of Two Different Enzyme...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry